Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monia Marchetti

Showing results (11-20 of 123) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancerNicola Lucio Liberato, Monia Marchetti, Giovanni Barosi
Expert Opinion on Pharmacotherapy|December 10, 2021
Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapyMonia Marchetti, Luca Albertin, Giulia Limberti, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthmaMonia Marchetti, Maria Cavallo, Elena Annoni, et al.
American Journal of Hematology|January 30, 2018
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic reviewMonia Marchetti, Alessandra Carobbio, Enrica Capitoni, et al.
Journal of Clinical Medicine|April 12, 2022
Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella AnalysisMonia Marchetti, Paolo Rivela, Claudia Bertassello, et al.
Clinical Drug Investigation|October 19, 2013
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysisCarla Rognoni, Monia Marchetti, Silvana Quaglini, et al.
Journal of Thrombosis and Thrombolysis|June 29, 2014
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysisCarla Rognoni, Monia Marchetti, Silvana Quaglini, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 11, 2005
What reimbursement for coronary revascularization with drug-eluting stents?Rosanna Tarricone, Monia Marchetti, Mark Lamotte, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 15, 2012
Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's diseaseMonia Marchetti, Nicola L Liberato, Antonio Di Sabatino, et al.
Internal and Emergency Medicine|October 20, 2011
Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel diseaseAntonio Di Sabatino, Lucio Liberato, Monia Marchetti, et al.
Pageof 13

Showing results (11-20 of 123) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancerNicola Lucio Liberato, Monia Marchetti, Giovanni Barosi
Expert Opinion on Pharmacotherapy|December 10, 2021
Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapyMonia Marchetti, Luca Albertin, Giulia Limberti, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthmaMonia Marchetti, Maria Cavallo, Elena Annoni, et al.
American Journal of Hematology|January 30, 2018
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic reviewMonia Marchetti, Alessandra Carobbio, Enrica Capitoni, et al.
Journal of Clinical Medicine|April 12, 2022
Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella AnalysisMonia Marchetti, Paolo Rivela, Claudia Bertassello, et al.
Clinical Drug Investigation|October 19, 2013
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysisCarla Rognoni, Monia Marchetti, Silvana Quaglini, et al.
Journal of Thrombosis and Thrombolysis|June 29, 2014
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysisCarla Rognoni, Monia Marchetti, Silvana Quaglini, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 11, 2005
What reimbursement for coronary revascularization with drug-eluting stents?Rosanna Tarricone, Monia Marchetti, Mark Lamotte, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 15, 2012
Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's diseaseMonia Marchetti, Nicola L Liberato, Antonio Di Sabatino, et al.
Internal and Emergency Medicine|October 20, 2011
Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel diseaseAntonio Di Sabatino, Lucio Liberato, Monia Marchetti, et al.
Pageof 13